703 related articles for article (PubMed ID: 30573284)
21. Intravenous thrombolysis with recombinant tissue plasminogen activator in a stroke patient treated with rivaroxaban.
Ishihara H; Torii H; Imoto H; Oka F; Sadahiro H; Suzuki M
J Stroke Cerebrovasc Dis; 2014; 23(10):e457-e459. PubMed ID: 25280819
[TBL] [Abstract][Full Text] [Related]
22. Derivation and Validation of a Scoring System for Intravenous Tissue Plasminogen Activator Use in Asian Patients.
Yeo LLL; Chien SC; Lin JR; Liow CW; Lee JD; Peng TI; Luen TH; Sharma V; Chan B; Lee TH;
J Stroke Cerebrovasc Dis; 2017 Aug; 26(8):1695-1703. PubMed ID: 28408066
[TBL] [Abstract][Full Text] [Related]
23. Reversing dabigatran effect with idarucizumab to enable intravenous thrombolysis in patients with acute ischaemic stroke - a single centre experience.
Włodarczyk E; Sawczyńska K; Wrona P; Słowik A
Neurol Neurochir Pol; 2023; 57(6):465-476. PubMed ID: 37955597
[TBL] [Abstract][Full Text] [Related]
24. Dabigatran Reversal Before Intravenous Tenecteplase in Acute Ischemic Stroke.
Beharry J; Waters MJ; Drew R; Fink JN; Wilson D; Campbell BCV; Parsons MW; Kleinig TJ; Wu TY
Stroke; 2020 May; 51(5):1616-1619. PubMed ID: 32208845
[TBL] [Abstract][Full Text] [Related]
25. High Plasma D-Dimer Indicates Unfavorable Outcome of Acute Ischemic Stroke Patients Receiving Intravenous Thrombolysis.
Hsu PJ; Chen CH; Yeh SJ; Tsai LK; Tang SC; Jeng JS
Cerebrovasc Dis; 2016; 42(1-2):117-21. PubMed ID: 27088493
[TBL] [Abstract][Full Text] [Related]
26. Safety of early initiation of rivaroxaban or dabigatran after thrombolysis in acute ischemic stroke.
Ritzenthaler T; Derex L; Davenas C; Bnouhanna W; Farghali A; Mechtouff L; Cho TH; Nighoghossian N
Rev Neurol (Paris); 2015 Sep; 171(8-9):613-5. PubMed ID: 25857461
[TBL] [Abstract][Full Text] [Related]
27. Dilemma of indication for thrombolysis in a patient with acute ischemic stroke treated with a novel oral anticoagulant.
Folyovich A; Varga V; Béres-Molnár KA; Vadasdi K; Bereczki D
J Stroke Cerebrovasc Dis; 2014 Mar; 23(3):580-2. PubMed ID: 23721623
[TBL] [Abstract][Full Text] [Related]
28. Ten-Year Evaluation of the TOYOTA Prehospital Stroke Scale for Tissue Plasminogen Activator Intravenous Therapy in the Real World.
Suzuki J; Nakai N; Kondo N; Tsuji H; Inagaki R; Furukawa S; Iwata M; Nishida S; Ito Y
Cerebrovasc Dis; 2018; 46(3-4):184-192. PubMed ID: 30384371
[TBL] [Abstract][Full Text] [Related]
29. Very Early versus Delayed Rehabilitation for Acute Ischemic Stroke Patients with Intravenous Recombinant Tissue Plasminogen Activator: A Nationwide Retrospective Cohort Study.
Momosaki R; Yasunaga H; Kakuda W; Matsui H; Fushimi K; Abo M
Cerebrovasc Dis; 2016; 42(1-2):41-8. PubMed ID: 26986718
[TBL] [Abstract][Full Text] [Related]
30. Real-World Outcomes of Acute Ischemic Stroke Treatment with Intravenous Recombinant Tissue Plasminogen Activator.
Betts KA; Hurley D; Song J; Sajeev G; Guo J; Du EX; Paschoalin M; Wu EQ
J Stroke Cerebrovasc Dis; 2017 Sep; 26(9):1996-2003. PubMed ID: 28689999
[TBL] [Abstract][Full Text] [Related]
31. Management of Dabigatran-Associated Bleeding with Two Doses of Idarucizumab Plus Hemodialysis.
Marino KK; Santiago RA; Dew RB; Berliner N; Connors JM; Connell NT; Tucker JK
Pharmacotherapy; 2016 Oct; 36(10):e160-e165. PubMed ID: 27581709
[TBL] [Abstract][Full Text] [Related]
32. Analyses of the Turkish National Intravenous Thrombolysis Registry.
Kutluk K; Kaya D; Afsar N; Arsava EM; Ozturk V; Uzuner N; Giray S; Topcuoglu MA; Gungor L; Sirin H; Yaka E; Ozdemir O; Dalkara T;
J Stroke Cerebrovasc Dis; 2016 May; 25(5):1041-1047. PubMed ID: 26853139
[TBL] [Abstract][Full Text] [Related]
33. Real-life experience with the specific reversal agent idarucizumab for the management of emergency situations in dabigatran-treated patients: a series of 11 cases.
Vosko MR; Bocksrucker C; Drwiła R; Dulíček P; Hauer T; Mutzenbach J; Schlimp CJ; Špinler D; Wolf T; Zugwitz D
J Thromb Thrombolysis; 2017 Apr; 43(3):306-317. PubMed ID: 28210988
[TBL] [Abstract][Full Text] [Related]
34. Treatment With Intravenous Alteplase for Acute Ischemic Stroke After Reversal of Dabigatran With Idarucizumab: A Case Study.
J Neurosci Nurs; 2019 Feb; 51(1):E1. PubMed ID: 30614937
[No Abstract] [Full Text] [Related]
35. Thrombolysis with alteplase for acute ischemic stroke patients with atrial fibrillation.
Zhang JB; Ding ZY; Yang Y; Sun W; Hai F; Sui XN; Li XY; Wang HZ; Wang XT; Zheng JL
Neurol Res; 2010 May; 32(4):353-8. PubMed ID: 20483000
[TBL] [Abstract][Full Text] [Related]
36. Imaging negative stroke: diagnoses and outcomes in intravenous tissue plasminogen activator-treated patients.
Spokoyny I; Raman R; Ernstrom K; Meyer BC; Hemmen TM
J Stroke Cerebrovasc Dis; 2014; 23(5):1046-50. PubMed ID: 24103663
[TBL] [Abstract][Full Text] [Related]
37. Idarucizumab for Reversal of Dabigatran Prior to Acute Surgery: A Schematic Approach Based on a Case Report.
Rosenberg L; Gerstrøm G; Nybo M
Basic Clin Pharmacol Toxicol; 2017 Apr; 120(4):407-410. PubMed ID: 27797449
[TBL] [Abstract][Full Text] [Related]
38. Idarucizumab for Intravenous Thrombolysis and Endovascular Thrombectomy in Acute Stroke: A Case Report.
Lin YT; Lai YJ; Lai TH
J Emerg Med; 2020 Mar; 58(3):e113-e116. PubMed ID: 31744711
[TBL] [Abstract][Full Text] [Related]
39. Fibrinogen concentrate replacement in ischemic stroke patients after recombinant tissue plasminogen activator treatment.
Vandelli L; Marietta M; Trenti T; Varani M; Bigliardi G; Rosafio F; Dell'acqua ML; Picchetto L; Nichelli P; Zini A
Adv Clin Exp Med; 2019 Feb; 28(2):219-222. PubMed ID: 30507073
[TBL] [Abstract][Full Text] [Related]
40. Tissue plasminogen activator thrombolytic therapy for acute ischemic stroke in 4 hospital groups in Japan.
Kono S; Deguchi K; Morimoto N; Kurata T; Deguchi S; Yamashita T; Ikeda Y; Matsuura T; Narai H; Omori N; Manabe Y; Yunoki T; Takao Y; Kawata S; Kashihara K; Abe K
J Stroke Cerebrovasc Dis; 2013 Apr; 22(3):190-6. PubMed ID: 21968092
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
